NOT-DA-20-016: Notice of NIDA Participation in PAR-20-036 "Getting To Zero: Understanding HIV Viral Suppression and Transmission in the United States (R01 Clinical Trial Optional)"

Notice of NIDA Participation in PAR-20-036 "Getting To Zero: Understanding HIV Viral Suppression and Transmission in the United States (R01 Clinical Trial Optional)"

Notice Number: NOT-DA-20-016

Key Dates
Release Date: December 5, 2019

Related Announcements
PAR 20-036

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this Notice is to inform potential applicants that the National Institute on Drug Abuse (NIDA) is participating in PAR 20-036 "Getting To Zero: Understanding HIV Viral Suppression and Transmission in the United States (R01 Clinical Trial Optional)".

The following sections have been updated to reflect the participation of NIDA in this FOA:

Part 1. Overview Information

Components of Participating Organizations

National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Mental Health (NIMH)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute on Drug Abuse (NIDA)

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.855; 93.242; 93.865; 93.279

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

NIDA is interested in the following areas of research involving people who use drugs (PWUD) including key populations (e.g., MSM, TW, FSW, HRH) where drug use is a common contributing HIV risk:

Studies of epidemiology of HIV transmission or care indicators (testing, transmission networks, linkage to care, engagement, and suppression of viral load) that provide methods for increasing accuracy and speed of providing data actionable data at jurisdictional or national population levels with particular attention the role of drug use
Studies that provide timely evaluation of HIV care, drug use, and drug treatment, stratified by substance use and other population-based factors such as gender, sexual risk, race, age, or geographic region.
Epidemiology research to understand long-term viral suppression and the correlates and predictors of success in relation to patterns of substance use, including injection practices.
Studies that provide timely evaluation of HIV care, drug use, and drug treatment, with specific attention to drug use and structural features of service delivery including variations in policy environments, service availability, service integration and financing of prevention and care services, including those related to substance use.
Research to uncover novel correlates and predictors of initial and sustained HIV viral suppression capitalizing on information related to contextual factors that may affect suppression, including changes in housing stability, transitions in and out of incarceration or other kinds of institutionalization or supervision (e.g., drug court, probation, parole, foster care).
Research regarding the role of participation in syringe service programs (SSPs) on viral suppression and on participation in services that provide pathways to viral suppression (e.g., HIV testing, referral to care, care adherence).
Research that focuses on the impact of stigma on access and utilization of care and success in preventing or treating HIV, with attention to stigmas related to drug use (e.g., drug user self-stigma, stigma anticipated from or enacted by providers, and stigma among providers around serving drug users).
Implementation science research that combines knowledge derived from epidemiology, data science and or modeling with on-the-ground experiences to improve viral suppression. Such research could focus on testing approaches to identify and diagnose hard-to-reach populations, strategies to improve service delivery, or strategies targeting structural and/or systems-level barriers to service delivery and ART adherence in substance using populations e.g. socio-economic marginalization, stigma, incarceration, poor access to substance use treatment, and destitution. Partnerships with care implementers and community are key elements of these studies.

In addition to the methods noted in PAR-20-036 https://grants.nih.gov/grants/guide/pa-files/PAR-20-036.html, NIDA encourages application of innovative approaches including system dynamics modeling and geographic information systems. Use of multiple sources of data sources is encouraged including strategies to link methodologically comparable datasets or utilize readily available public use and administrative data.

Part 2. Section VII. Agency Contacts

Scientific/Research Contact(s)

Richard A. Jenkins, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-1923
Email: jenkinsri@mail.nih.gov

Financial/Grants Management Contact(s)

Pam Fleming
National Institute on Drug Abuse (NIDA)
Telephone: 301-480-1159
Email: pfleming@mail.nih.gov

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Richard A. Jenkins, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-1923
Email: jenkinsri@mail.nih.gov